AD Pipeline Watch: First Patient Dosed in Phase 2b Clinical Trial Program of Zabalafin Hydrogel
The first patient has been dosed in Alphyn’s CLEAR-AD1 Phase 2b clinical trial of Zabalafin Hydrogel in atopic dermatitis (AD) in Australia.
Day: April 8, 2025